Free Trial
NASDAQ:RXRX

Recursion Pharmaceuticals (RXRX) Stock Price, News & Analysis

Recursion Pharmaceuticals logo
$5.36 -0.17 (-2.98%)
As of 11:04 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Recursion Pharmaceuticals Stock (NASDAQ:RXRX)

Advanced

Key Stats

Today's Range
$5.35
$5.60
50-Day Range
$4.52
$5.95
52-Week Range
$3.79
$12.36
Volume
11.26 million shs
Average Volume
25.11 million shs
Market Capitalization
$2.33 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.25
Consensus Rating
Hold

Company Overview

Recursion Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
50th Percentile Overall Score

RXRX MarketRank™: 

Recursion Pharmaceuticals scored higher than 50% of companies evaluated by MarketBeat, and ranked 574th out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Recursion Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.17, and is based on 2 buy ratings, 3 hold ratings, and 1 sell rating.

  • Upside Potential

    Recursion Pharmaceuticals has a consensus price target of $7.25, representing about 34.1% upside from its current price of $5.41.

  • Amount of Analyst Coverage

    Recursion Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

  • Read more about Recursion Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Recursion Pharmaceuticals are expected to grow in the coming year, from ($1.57) to ($1.42) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Recursion Pharmaceuticals is -3.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Recursion Pharmaceuticals is -3.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Recursion Pharmaceuticals has a P/B Ratio of 2.07. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Recursion Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    39.65% of the float of Recursion Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Recursion Pharmaceuticals has a short interest ratio ("days to cover") of 5.3.
  • Change versus previous month

    Short interest in Recursion Pharmaceuticals has recently increased by 6.42%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Recursion Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Recursion Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    39.65% of the float of Recursion Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Recursion Pharmaceuticals has a short interest ratio ("days to cover") of 5.3.
  • Change versus previous month

    Short interest in Recursion Pharmaceuticals has recently increased by 6.42%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Recursion Pharmaceuticals has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Recursion Pharmaceuticals this week, compared to 10 articles on an average week.
  • Search Interest

    111 people have searched for RXRX on MarketBeat in the last 30 days. This is an increase of 79% compared to the previous 30 days.
  • MarketBeat Follows

    48 people have added Recursion Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 118% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Recursion Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $202,026.00 in company stock.

  • Percentage Held by Insiders

    Only 8.43% of the stock of Recursion Pharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    89.06% of the stock of Recursion Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Recursion Pharmaceuticals' insider trading history.
Receive RXRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Recursion Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

RXRX Stock News Headlines

Needham Reiterates a Buy on Recursion Pharmaceuticals (RXRX)
​9 AI Stocks Set to Soar Amid U.S.-China Trade Tensions
The escalating U.S.-China trade tensions are reshaping the AI landscape. Companies like Nvidia are facing significant revenue hits with the U.S. imposing new export restrictions on advanced AI chips to China. This shift opens doors for U.S.-based AI companies poised to fill the gap.tc pixel
10 Hidden-Gem AI Stocks to Buy Right Now
See More Headlines

RXRX Stock Analysis - Frequently Asked Questions

Recursion Pharmaceuticals' stock was trading at $6.76 at the start of the year. Since then, RXRX shares have decreased by 20.0% and is now trading at $5.4050.

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) announced its quarterly earnings results on Tuesday, August, 5th. The company reported ($0.41) earnings per share for the quarter, missing analysts' consensus estimates of ($0.35) by $0.06. The company's quarterly revenue was up 33.3% on a year-over-year basis.
Read the conference call transcript
.

Recursion Pharmaceuticals (RXRX) raised $306 million in an IPO on Friday, April 16th 2021. The company issued 18,000,000 shares at $16.00-$18.00 per share. Goldman Sachs, J.P. Morgan, BofA Securities, SVB Leerink, Allen & Co. and KeyBanc Capital Markets served as the underwriters for the IPO.

Shares of RXRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Recursion Pharmaceuticals investors own include NVIDIA (NVDA), Invesco QQQ (QQQ), Meta Platforms (META), Broadcom (AVGO), CrowdStrike (CRWD) and Advanced Micro Devices (AMD).

Company Calendar

Last Earnings
8/05/2025
Today
10/07/2025
Next Earnings (Estimated)
11/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:RXRX
CIK
1601830
Employees
400
Year Founded
2013

Price Target and Rating

High Price Target
$10.00
Low Price Target
$5.00
Potential Upside/Downside
+31.1%
Consensus Rating
Hold
Rating Score (0-4)
2.17
Research Coverage
6 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.78)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$463.66 million
Net Margins
-1,004.91%
Pretax Margin
-1,004.88%
Return on Equity
-76.09%
Return on Assets
-54.29%

Debt

Debt-to-Equity Ratio
0.02
Current Ratio
3.58
Quick Ratio
3.58

Sales & Book Value

Annual Sales
$58.84 million
Price / Sales
40.80
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.61 per share
Price / Book
2.12

Miscellaneous

Outstanding Shares
434,150,000
Free Float
397,553,000
Market Cap
$2.40 billion
Optionable
Optionable
Beta
0.91

Social Links

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

This page (NASDAQ:RXRX) was last updated on 10/7/2025 by MarketBeat.com Staff
From Our Partners